<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01903005</url>
  </required_header>
  <id_info>
    <org_study_id>OX219-008</org_study_id>
    <nct_id>NCT01903005</nct_id>
  </id_info>
  <brief_title>Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence</brief_title>
  <official_title>A Multi-center, Open-Label, 24-Week, Follow-Up Study to Assess Safety, Efficacy, and Treatment Adherence For Maintenance Treatment of Opioid Dependence With OX219</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orexo AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Orexo AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess safety, efficacy, and treatment retention following
      extended treatment with OX219, a higher-bioavailability buprenorphine/naloxone (BNX)
      sublingual tablet formulation in opioid-dependent patients who completed 1 of 2 primary
      efficacy and safety studies of OX219.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multicenter, open-label, uncontrolled, single-arm, 24-week, extension study to
      assess safety, efficacy, and treatment retention during maintenance treatment.

      Eligible patients had completed 1 of 2 primary efficacy and safety studies of the
      higher-bioavailability BNX sublingual tablet formulation (primary study OX219-006
      [NCT01908842] or OX219-007 [NCT01848054]). The total duration of study treatment was 24
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Reporting Treatment-Emergent Adverse Events</measure>
    <time_frame>Day 1 through week 24</time_frame>
    <description>Number of patients reporting treatment-emergent adverse events during open-label, extension treatment with higher bioavailability BNX sublingual tablets</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Reporting Treatment-Related, Treatment-Emergent Adverse Events</measure>
    <time_frame>Day 1 through week 24</time_frame>
    <description>Treatment-emergent adverse events considered related to treatment with the higher bioavailability BNX sublingual tablets</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Reporting Treatment-Emergent Serious Adverse Events</measure>
    <time_frame>Day 1 throught week 24</time_frame>
    <description>Patients reporting treatment-emergent serious adverse events considered either related or not related to treatment with the higher bioavailability BNX sublingual tablets</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patient Discontinuations Due to Treatment-Emergent Adverse Events</measure>
    <time_frame>Day 1 through week 24</time_frame>
    <description>Study discontinuations due to treatment-emergent adverse events that occurred during treatment with bioavailability BNX sublingual tablets</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention in Treatment in the Safety Population</measure>
    <time_frame>Treatment retention was assessed at weeks 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Retention in treatment by visit in the safety population at weeks 4, 8, 12, 16, 20, and 24, defined as the number of patients receiving treatment on the day of the visit (Â± 5 days for each visit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Primary Study Baseline (OX219-006 or OX219-007) in Clinical Opioid Withdrawal Scale (COWS) Score</measure>
    <time_frame>Prior to dosing on day 1, at weeks 4, 8,12,16, 20, 24, and at study endpoint</time_frame>
    <description>Mean change from primary study baseline in COWS total scores during the 24-week open-label, extension study; COWS scores range from 0 to 48, with a lower score being more favorable; study endpoint was defined as the last post-baseline value recorded for COWS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Primary Study Baseline (OX219-006 or OX219-007) in Subjective Opioid Withdrawal Scale (SOWS) Score</measure>
    <time_frame>Prior to dosing on day 1, at weeks 4, 8,12,16, 20, and 24, and at study endpoint</time_frame>
    <description>Mean change from primary study baseline in SOWS total scores during the 24-week open-label, extension study; SOWS scores range from 0 to 64, with a lower score being more favorable; study endpoint was defined as the last post-baseline value recorded for SOWS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Primary Study Baseline (OX219-006 and OX219-007) in Visual Analog Scale (VAS) Craving Scores</measure>
    <time_frame>Prior to dosing on day 1, at weeks 4, 8, 12, 16, 20, and 24, and at study endpoint</time_frame>
    <description>Mean change from primary study baseline in VAS craving scores during the 24-week open-label, extension study; VAS craving scores range from 0 (&quot;no cravings&quot;) to 100 mm (&quot;most intense craving I have ever had&quot;); study endpoint was defined as the last post-baseline value recorded for VAS craving</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Primary Study Baseline (OX219-006 or OX219-007) for Question 1 of the Work Productivity/Activity Impairment: 6-Question Specific Health Problem Questionnaire (WPAI:SHP)</measure>
    <time_frame>Study Endpoint</time_frame>
    <description>Question 1 of the WPAI:SHP asks patients to provide a &quot;yes&quot; or &quot;no&quot; response to the question &quot;Are you employed?&quot;; The percentage of patients employed at the end of the 24-week open-label, extension study was calculated by subtracting the percentage of previously employed patients not employed at study end from the percentage of previously unemployed patients who were employed by study end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Primary Study Baseline (OX219-006 or OX219-007) for Questions 2-4 of the WPAI:SHP</measure>
    <time_frame>Week 24</time_frame>
    <description>Mean change from primary study baseline to week 24 of the open-label, extension study for questions 2-4 of the WPAI:SHP; Question 2: During the past 7 days, how many hours did you miss from work because of problems associated with your opioid dependence?; Question 3: During the past 7 days, how many hours did you miss from work because of any other reason, such as vacation, holidays, time off to participate in this study?; Question 4: During the past 7 days, how many hours did you actually work?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Primary Study Baseline (OX219-006 or OX219-007) for Questions 5-6 of the WPAI:SHP</measure>
    <time_frame>Week 24</time_frame>
    <description>Mean change from primary study baseline to week 24 of the open-label extension study for questions 5-6 of the WPAI:SHP; Question 5: During the past 7 days, how much did your opioid dependence affect your productivity while you were working?; Question 6: During the past 7 days, how much did your opioid dependence affect your ability to do regular daily activities, other than work at a job?; Questions 5 and 6 of the WPAI:SHP are scored on an 11-point scale (0 = problem had no effect; 10 = problem completely prevented me from doing my work/daily activities)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">668</enrollment>
  <condition>Opioid Dependence, on Agonist Therapy</condition>
  <arm_group>
    <arm_group_label>Open-label BNX sublingual tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Higher bioavailability BNX sublingual tablets</intervention_name>
    <description>Once daily, open-label treatment with higher bioavailability BNX sublingual tablets for 24 weeks</description>
    <arm_group_label>Open-label BNX sublingual tablets</arm_group_label>
    <other_name>OX219</other_name>
    <other_name>Zubsolv</other_name>
    <other_name>Buprenorphine/naloxone sublingual tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Signed informed consent form.

          -  Completion of 1 of 2 primary efficacy safety studies of BNX sublingual tablets
             (OX219-006 or OX219-007).

          -  Female patients of child bearing potential who used a reliable method of contraception
             (hormonal, condom with spermicide, intrauterine device) during the previous OX219-006
             or OX219-007 study and continue to use it for the OX219-008 study. Females who are not
             of child-bearing potential who are either surgically sterile (by hysterectomy,
             bilateral oophorectomy, bilateral salpingectomy, or tubal ligation), or
             postmenopausal, as defined by being at least 50 years of age and having had an absence
             of menses for at least 2 years, were also eligible.

        Exclusion criteria

          -  Females who are pregnant (positive pregnancy test result) or lactating, or planning to
             become pregnant during the study.

          -  Participants who are unwilling or unable to comply with the requirements of the
             protocol (eg, pending incarceration) or are in a situation or condition that, in the
             opinion of the investigator, may interfere with participation in the study.

          -  Participants who are participating in any other clinical study in which medication(s)
             are being delivered or who had used an investigational drug or device within the last
             30 days.

          -  Participants with any known allergy or sensitivity or intolerance to buprenorphine,
             naloxone, or any related drug, or history of any drug hypersensitivity or intolerance
             that, in the opinion of the investigator, would compromise the safety of the subject
             or the study.

          -  Participant with a contra-indicated serious medical condition.

          -  Participants who are at suicidal risk as determined by any of the following: a history
             of suicidal ideation â¤ 3 months prior to baseline with a score of 4 (intent to act) or
             5 (specified plan and intent) on the Columbia Suicide Severity Risk Scale (C-SSRS).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kent Hoffman</last_name>
    <role>Principal Investigator</role>
    <affiliation>TRY Research, 406 Lake Howell Road, Maitland, Florida 32751</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Jefferson County</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marion County</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston County</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maricopa County</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles County</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego County</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Broward County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duval County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville metropolitan area</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami-Dade County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando metropolitan area</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osceola County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Beach County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeKalb County</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago metropolitan area</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore County</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol County</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rankin County</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis metropolitan area</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warren County</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma County</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland metropolitan area</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delaware County</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia County</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston County</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake County</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Benton County</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2013</study_first_posted>
  <results_first_submitted>August 17, 2015</results_first_submitted>
  <results_first_submitted_qc>September 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 28, 2015</results_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid, Dependence, agonist, Buprenorphine, Naloxone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 668 patients who completed primary study OX219-006 (NCT01908842) or OX219-007 (NCT01848054) were enrolled. Three patients entered the study without taking any study medication and were excluded. A total of 665 patients were included in the data analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Safety Population</title>
          <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="665">Primary study OX219-006 (n=475); Primary study OX219-007 (n=190)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="292">Primary study OX219-006 (n=194); Primary study OX219-007 (n=98)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="373"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population</population>
      <group_list>
        <group group_id="B1">
          <title>OX219-006 Completers</title>
          <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg and 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
        </group>
        <group group_id="B2">
          <title>OX219-007 Completers</title>
          <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg and 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="475"/>
            <count group_id="B2" value="190"/>
            <count group_id="B3" value="665"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.9" spread="11.4"/>
                    <measurement group_id="B2" value="39.0" spread="10.8"/>
                    <measurement group_id="B3" value="36.8" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="279"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="410"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="402"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.99" spread="9.43"/>
                    <measurement group_id="B2" value="173.35" spread="10.01"/>
                    <measurement group_id="B3" value="172.38" spread="9.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.34" spread="18.99"/>
                    <measurement group_id="B2" value="78.98" spread="20.73"/>
                    <measurement group_id="B3" value="78.53" spread="19.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.47" spread="6.11"/>
                    <measurement group_id="B2" value="26.26" spread="6.63"/>
                    <measurement group_id="B3" value="26.41" spread="6.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Opioid Use</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.20" spread="9.50"/>
                    <measurement group_id="B2" value="9.6" spread="8.79"/>
                    <measurement group_id="B3" value="7.95" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Retention in Treatment in the Safety Population</title>
        <description>Retention in treatment by visit in the safety population at weeks 4, 8, 12, 16, 20, and 24, defined as the number of patients receiving treatment on the day of the visit (Â± 5 days for each visit)</description>
        <time_frame>Treatment retention was assessed at weeks 4, 8, 12, 16, 20, and 24</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Population</title>
            <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Retention in Treatment in the Safety Population</title>
          <description>Retention in treatment by visit in the safety population at weeks 4, 8, 12, 16, 20, and 24, defined as the number of patients receiving treatment on the day of the visit (Â± 5 days for each visit)</description>
          <population>Safety population</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="563" lower_limit="545" upper_limit="581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="483" lower_limit="460" upper_limit="505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425" lower_limit="401" upper_limit="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="383" lower_limit="358" upper_limit="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333" lower_limit="308" upper_limit="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292" lower_limit="267" upper_limit="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Primary Study Baseline (OX219-006 or OX219-007) in Clinical Opioid Withdrawal Scale (COWS) Score</title>
        <description>Mean change from primary study baseline in COWS total scores during the 24-week open-label, extension study; COWS scores range from 0 to 48, with a lower score being more favorable; study endpoint was defined as the last post-baseline value recorded for COWS</description>
        <time_frame>Prior to dosing on day 1, at weeks 4, 8,12,16, 20, 24, and at study endpoint</time_frame>
        <population>Safety population; patient population at day 1 (n=658) is lower than overall safety population (n=665) due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Population</title>
            <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Primary Study Baseline (OX219-006 or OX219-007) in Clinical Opioid Withdrawal Scale (COWS) Score</title>
          <description>Mean change from primary study baseline in COWS total scores during the 24-week open-label, extension study; COWS scores range from 0 to 48, with a lower score being more favorable; study endpoint was defined as the last post-baseline value recorded for COWS</description>
          <population>Safety population; patient population at day 1 (n=658) is lower than overall safety population (n=665) due to missing data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=658)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.0" lower_limit="-12.3" upper_limit="-11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=557)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" lower_limit="-12.6" upper_limit="-11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=477)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.7" lower_limit="-13.1" upper_limit="-12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.9" lower_limit="-13.4" upper_limit="-12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.1" lower_limit="-13.6" upper_limit="-12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" lower_limit="-13.8" upper_limit="-12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (completers only; n=288)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.1" lower_limit="-13.7" upper_limit="-12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Endpoint (n=597)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" lower_limit="-12.9" upper_limit="-12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Primary Study Baseline (OX219-006 or OX219-007) in Subjective Opioid Withdrawal Scale (SOWS) Score</title>
        <description>Mean change from primary study baseline in SOWS total scores during the 24-week open-label, extension study; SOWS scores range from 0 to 64, with a lower score being more favorable; study endpoint was defined as the last post-baseline value recorded for SOWS</description>
        <time_frame>Prior to dosing on day 1, at weeks 4, 8,12,16, 20, and 24, and at study endpoint</time_frame>
        <population>Safety population; patient population at day 1 (n=650) is lower than overall safety population (n=665) due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Population</title>
            <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Primary Study Baseline (OX219-006 or OX219-007) in Subjective Opioid Withdrawal Scale (SOWS) Score</title>
          <description>Mean change from primary study baseline in SOWS total scores during the 24-week open-label, extension study; SOWS scores range from 0 to 64, with a lower score being more favorable; study endpoint was defined as the last post-baseline value recorded for SOWS</description>
          <population>Safety population; patient population at day 1 (n=650) is lower than overall safety population (n=665) due to missing data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=650)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.8" lower_limit="-27.8" upper_limit="-25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=550)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.4" lower_limit="-28.6" upper_limit="-26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.0" lower_limit="-29.2" upper_limit="-26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.7" lower_limit="-29.0" upper_limit="-26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=376)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.7" lower_limit="-30.1" upper_limit="-27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=331)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.9" lower_limit="-30.4" upper_limit="-27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=282)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.7" lower_limit="-29.4" upper_limit="-26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Endpoint (n=588)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.3" lower_limit="-28.5" upper_limit="-26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Primary Study Baseline (OX219-006 and OX219-007) in Visual Analog Scale (VAS) Craving Scores</title>
        <description>Mean change from primary study baseline in VAS craving scores during the 24-week open-label, extension study; VAS craving scores range from 0 (&quot;no cravings&quot;) to 100 mm (&quot;most intense craving I have ever had&quot;); study endpoint was defined as the last post-baseline value recorded for VAS craving</description>
        <time_frame>Prior to dosing on day 1, at weeks 4, 8, 12, 16, 20, and 24, and at study endpoint</time_frame>
        <population>Safety population; patient population at day 1 (n=646) is lower than overall safety population (n=665) due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Population</title>
            <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Primary Study Baseline (OX219-006 and OX219-007) in Visual Analog Scale (VAS) Craving Scores</title>
          <description>Mean change from primary study baseline in VAS craving scores during the 24-week open-label, extension study; VAS craving scores range from 0 (&quot;no cravings&quot;) to 100 mm (&quot;most intense craving I have ever had&quot;); study endpoint was defined as the last post-baseline value recorded for VAS craving</description>
          <population>Safety population; patient population at day 1 (n=646) is lower than overall safety population (n=665) due to missing data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=646)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.8" lower_limit="-55.0" upper_limit="-50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=563)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.6" lower_limit="-59.0" upper_limit="-54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=479)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59.4" lower_limit="-62.0" upper_limit="-56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=426)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59.4" lower_limit="-62.0" upper_limit="-56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.5" lower_limit="-64.1" upper_limit="-58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.4" lower_limit="-64.3" upper_limit="-58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=289)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.5" lower_limit="-63.8" upper_limit="-57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Endpoint (n=598)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.3" lower_limit="-59.6" upper_limit="-55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Primary Study Baseline (OX219-006 or OX219-007) for Question 1 of the Work Productivity/Activity Impairment: 6-Question Specific Health Problem Questionnaire (WPAI:SHP)</title>
        <description>Question 1 of the WPAI:SHP asks patients to provide a &quot;yes&quot; or &quot;no&quot; response to the question &quot;Are you employed?&quot;; The percentage of patients employed at the end of the 24-week open-label, extension study was calculated by subtracting the percentage of previously employed patients not employed at study end from the percentage of previously unemployed patients who were employed by study end</description>
        <time_frame>Study Endpoint</time_frame>
        <population>Safety population; patients with missing data were excluded from the analysis and are reflected in the number of patients analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Population</title>
            <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Primary Study Baseline (OX219-006 or OX219-007) for Question 1 of the Work Productivity/Activity Impairment: 6-Question Specific Health Problem Questionnaire (WPAI:SHP)</title>
          <description>Question 1 of the WPAI:SHP asks patients to provide a &quot;yes&quot; or &quot;no&quot; response to the question &quot;Are you employed?&quot;; The percentage of patients employed at the end of the 24-week open-label, extension study was calculated by subtracting the percentage of previously employed patients not employed at study end from the percentage of previously unemployed patients who were employed by study end</description>
          <population>Safety population; patients with missing data were excluded from the analysis and are reflected in the number of patients analyzed</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unemployed at baseline; employed at study endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Employed at baseline; unemployed at study endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase in patients employed at study endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Primary Study Baseline (OX219-006 or OX219-007) for Questions 2-4 of the WPAI:SHP</title>
        <description>Mean change from primary study baseline to week 24 of the open-label, extension study for questions 2-4 of the WPAI:SHP; Question 2: During the past 7 days, how many hours did you miss from work because of problems associated with your opioid dependence?; Question 3: During the past 7 days, how many hours did you miss from work because of any other reason, such as vacation, holidays, time off to participate in this study?; Question 4: During the past 7 days, how many hours did you actually work?</description>
        <time_frame>Week 24</time_frame>
        <population>Safety population; patients with missing data were excluded from the analysis and are reflected in the number of participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Population</title>
            <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Primary Study Baseline (OX219-006 or OX219-007) for Questions 2-4 of the WPAI:SHP</title>
          <description>Mean change from primary study baseline to week 24 of the open-label, extension study for questions 2-4 of the WPAI:SHP; Question 2: During the past 7 days, how many hours did you miss from work because of problems associated with your opioid dependence?; Question 3: During the past 7 days, how many hours did you miss from work because of any other reason, such as vacation, holidays, time off to participate in this study?; Question 4: During the past 7 days, how many hours did you actually work?</description>
          <population>Safety population; patients with missing data were excluded from the analysis and are reflected in the number of participants analyzed</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Missed work hours due to opioid dependence (n=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" lower_limit="-8.1" upper_limit="-1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missed work hours due to other reason (n=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-1.9" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of hours actually worked (n=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="3.4" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Primary Study Baseline (OX219-006 or OX219-007) for Questions 5-6 of the WPAI:SHP</title>
        <description>Mean change from primary study baseline to week 24 of the open-label extension study for questions 5-6 of the WPAI:SHP; Question 5: During the past 7 days, how much did your opioid dependence affect your productivity while you were working?; Question 6: During the past 7 days, how much did your opioid dependence affect your ability to do regular daily activities, other than work at a job?; Questions 5 and 6 of the WPAI:SHP are scored on an 11-point scale (0 = problem had no effect; 10 = problem completely prevented me from doing my work/daily activities)</description>
        <time_frame>Week 24</time_frame>
        <population>Safety population; patients with missing data were excluded from the analysis and are reflected in the number of participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Population</title>
            <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Primary Study Baseline (OX219-006 or OX219-007) for Questions 5-6 of the WPAI:SHP</title>
          <description>Mean change from primary study baseline to week 24 of the open-label extension study for questions 5-6 of the WPAI:SHP; Question 5: During the past 7 days, how much did your opioid dependence affect your productivity while you were working?; Question 6: During the past 7 days, how much did your opioid dependence affect your ability to do regular daily activities, other than work at a job?; Questions 5 and 6 of the WPAI:SHP are scored on an 11-point scale (0 = problem had no effect; 10 = problem completely prevented me from doing my work/daily activities)</description>
          <population>Safety population; patients with missing data were excluded from the analysis and are reflected in the number of participants analyzed</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Problem affects work productivity (n=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" lower_limit="-4.7" upper_limit="-3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Problem affects daily activities (n=283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" lower_limit="-4.8" upper_limit="-3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Reporting Treatment-Emergent Adverse Events</title>
        <description>Number of patients reporting treatment-emergent adverse events during open-label, extension treatment with higher bioavailability BNX sublingual tablets</description>
        <time_frame>Day 1 through week 24</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Population</title>
            <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reporting Treatment-Emergent Adverse Events</title>
          <description>Number of patients reporting treatment-emergent adverse events during open-label, extension treatment with higher bioavailability BNX sublingual tablets</description>
          <population>Safety population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Reporting Treatment-Related, Treatment-Emergent Adverse Events</title>
        <description>Treatment-emergent adverse events considered related to treatment with the higher bioavailability BNX sublingual tablets</description>
        <time_frame>Day 1 through week 24</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Population</title>
            <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reporting Treatment-Related, Treatment-Emergent Adverse Events</title>
          <description>Treatment-emergent adverse events considered related to treatment with the higher bioavailability BNX sublingual tablets</description>
          <population>Safety population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Reporting Treatment-Emergent Serious Adverse Events</title>
        <description>Patients reporting treatment-emergent serious adverse events considered either related or not related to treatment with the higher bioavailability BNX sublingual tablets</description>
        <time_frame>Day 1 throught week 24</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Population</title>
            <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reporting Treatment-Emergent Serious Adverse Events</title>
          <description>Patients reporting treatment-emergent serious adverse events considered either related or not related to treatment with the higher bioavailability BNX sublingual tablets</description>
          <population>Safety population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Possibly treatment-related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not treatment-related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patient Discontinuations Due to Treatment-Emergent Adverse Events</title>
        <description>Study discontinuations due to treatment-emergent adverse events that occurred during treatment with bioavailability BNX sublingual tablets</description>
        <time_frame>Day 1 through week 24</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Population</title>
            <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patient Discontinuations Due to Treatment-Emergent Adverse Events</title>
          <description>Study discontinuations due to treatment-emergent adverse events that occurred during treatment with bioavailability BNX sublingual tablets</description>
          <population>Safety population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 through Week 24 of Open-Label Extension Study</time_frame>
      <desc>Safety population (N=665)</desc>
      <group_list>
        <group group_id="E1">
          <title>Safety Population</title>
          <description>Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses of buprenorphine/naloxone between 5.7/1.4 mg and 17.1/4.2 mg mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="665"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive and atherosclerotic cardiovascular disease</sub_title>
                <description>Condition led to death; non-treatment-emergent, not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="665"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory syncytial virus bronchitis</sub_title>
                <description>Moderate, treatment-emergent; not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="665"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <description>Severe, treatment-emergent; unlikely related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="665"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Severe, treatment-emergent; not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="665"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Heroin toxicity</sub_title>
                <description>Condition led to death; non-treatment-emergent; not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="665"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <description>Moderate, treatment-emergent; not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="665"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <description>Severe, treatment-emergent; not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="665"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <description>Severe, treatment-emergent; not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="665"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <description>Severe, treatment-emergent; not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="665"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <description>Mild, treatment-emergent; not related to study drug in one patient; severe, treatment-emergent; possibly related to study drug in another patient.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="665"/>
              </event>
              <event>
                <sub_title>Worsening of opioid dependence</sub_title>
                <description>Moderate, non-treatment-emergent; not related to study drug in two patients.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="665"/>
              </event>
              <event>
                <sub_title>Bipolar depression</sub_title>
                <description>Severe, non-treatment-emergent; unlikely related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="665"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <description>Moderate, treatment-emergent; not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="665"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <description>Moderate, treatment-emergent; not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="665"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <description>Moderate, treatment-emergent; not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="665"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <description>Severe, non-treatment-emergent; not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="665"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 16.0.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="665"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Treatment-emergent.</description>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="665"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Treatment-emergent.</description>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="665"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kent Hoffman, DO</name_or_title>
      <organization>TRY Research</organization>
      <phone>(407) 691-3960</phone>
      <email>Suboxdoc1@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

